Κωδικός Συσκ. ΕΟΦ Ονο
Chiesi Hellas
Chiesi Farmaceutici completes the acquisition of European Marketing Rights
Curosurf ® 120 mg/240 mg
Silver nanowire interactions with primary human alveolar type-II epithelial cell secretions: contrasting bioreactivity with human alveolar type-I and ... - Nanoscale (RSC Publishing) DOI:10.1039/C5NR01496D
About Chiesi Our history Mission and Values Οικονομικές Καταστάσεις Disclosure Annual and Sustainability Report B Corp Pharmacovigilance Therapeutic areas Respiratory Neonatology Rare Diseases Contacts Product Portfolio Respiratory Neonatology ...
PDF) Effects of the New Generation Synthetic Reconstituted Surfactant CHF5633 on Pro- and Anti-Inflammatory Cytokine Expression in Native and LPS-Stimulated Adult CD14+ Monocytes
Service Customer Service Patientservice Medical Suggestions Pharmacovigilance data privacy/ cookies Products Sustainability Our approach We ACT - Sustainability Manifesto Environment Supply Chain Sustainability Ethics and Transparency ...
Curosurf
About Chiesi Our history Mission and Values Οικονομικές Καταστάσεις Disclosure Annual and Sustainability Report B Corp Pharmacovigilance Therapeutic areas Respiratory Neonatology Rare Diseases Contacts Product Portfolio Respiratory Neonatology ...
PDF) Effect of pulmonary surfactant on the dissolution, stability and uptake of zinc oxide nanowires by human respiratory epithelial cells
About Chiesi Our history Mission and Values Οικονομικές Καταστάσεις Disclosure Annual and Sustainability Report B Corp Pharmacovigilance Therapeutic areas Respiratory Neonatology Rare Diseases Contacts Product Portfolio Respiratory Neonatology ...
About Chiesi Our history Mission and Values Οικονομικές Καταστάσεις Disclosure Annual and Sustainability Report B Corp Pharmacovigilance Therapeutic areas Respiratory Neonatology Rare Diseases Contacts Product Portfolio Respiratory Neonatology ...
Ioannis Gianniotis - Medical Representative - Chiesi Hellas | LinkedIn
Silver nanowire interactions with primary human alveolar type-II epithelial cell secretions: contrasting bioreactivity with human alveolar type-I and ... - Nanoscale (RSC Publishing) DOI:10.1039/C5NR01496D
PDF) Improved Less Invasive Surfactant Administration Success in Preterm Infants after Procedure Standardization
Ioannis Gianniotis - Medical Representative - Chiesi Hellas | LinkedIn
The LISAcath catheter (left) and Angiocath catheter (right). | Download Scientific Diagram
PDF) Effects of the New Generation Synthetic Reconstituted Surfactant CHF5633 on Pro- and Anti-Inflammatory Cytokine Expression in Native and LPS-Stimulated Adult CD14+ Monocytes
Ioannis Gianniotis - Medical Representative - Chiesi Hellas | LinkedIn
Chiesi Hellas | LinkedIn
About Chiesi Our history Mission and Values Οικονομικές Καταστάσεις Disclosure Annual and Sustainability Report B Corp Pharmacovigilance Therapeutic areas Respiratory Neonatology Rare Diseases Contacts Product Portfolio Respiratory Neonatology ...
About Chiesi Our history Mission and Values Οικονομικές Καταστάσεις Disclosure Annual and Sustainability Report B Corp Pharmacovigilance Therapeutic areas Respiratory Neonatology Rare Diseases Contacts Product Portfolio Respiratory Neonatology ...
About Chiesi Our history Mission and Values Οικονομικές Καταστάσεις Disclosure Annual and Sustainability Report B Corp Pharmacovigilance Therapeutic areas Respiratory Neonatology Rare Diseases Contacts Product Portfolio Respiratory Neonatology ...
About Chiesi Our history Mission and Values Οικονομικές Καταστάσεις Disclosure Annual and Sustainability Report B Corp Pharmacovigilance Therapeutic areas Respiratory Neonatology Rare Diseases Contacts Product Portfolio Respiratory Neonatology ...
PDF) Impact of the New Generation Reconstituted Surfactant CHF5633 on Human CD4+ Lymphocytes
PDF) Impact of the New Generation Reconstituted Surfactant CHF5633 on Human CD4+ Lymphocytes
Influence of surfactant preparations on proliferation ability of... | Download Scientific Diagram
About Chiesi Our history Mission and Values Οικονομικές Καταστάσεις Disclosure Annual and Sustainability Report B Corp Pharmacovigilance Therapeutic areas Respiratory Neonatology Rare Diseases Contacts Product Portfolio Respiratory Neonatology ...
